San Mateo, United States
Genesis Molecular AI, founded in 2019, stands at the intersection of AI and Biotechnology, with a mission encapsulated in its slogan: "Unifying AI and Biotech to accelerate the discovery of new medicines." Headquartered in Burlingame, CA, with strategic locations in San Diego and New York, Genesis is pushing the boundaries of drug design and development through its innovative platform.
The company's proprietary technology, GEMS (Genesis Exploration of Molecular Space), is a cutting-edge AI platform that marries artificial intelligence with physical modeling to optimize small molecule drug discovery. This includes their noteworthy generative diffusion model Pearl for structure prediction. GEMS accelerate drug development from hit identification through lead optimization by iterating the design and synthesis of promising drug candidates.
Genesis has constructed an internal pipeline geared towards high-value targets, particularly those that are data-poor or traditionally considered undruggable. The company has also secured collaborations with prominent entities like Gilead and Incyte.
To date, Genesis has successfully attracted over $300M from noteworthy investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures, BlackRock, and Menlo Ventures. The most recent investment was from nVentures in November 2024, marking a late-stage venture funding phase.
iktos
Menten AI
